Fate Therapeutics Q3 Earnings Beat Estimates, Revenue Surges 104.82%

Fate Therapeutics reported a Q3 loss of $0.27 per share, beating the Zacks Consensus Estimate of a loss of $0.29. The company's revenue was $1.74 million, surpassing the Zacks Consensus Estimate by 104.82%. Shares have lost 37% YTD. The company has a Zacks Rank #4 (Sell) due to an unfavorable estimate revisions trend. Investors should monitor the company's earnings outlook, which is expected to change following the earnings report.